Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Syncona Limited LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.60 -0.31% 194.40 194.00 194.40 195.20 194.40 195.20 36,486 09:02:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 25.4 15.5 2.3 83.1 1,301

Syncona Share Discussion Threads

Showing 18726 to 18749 of 18900 messages
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
DateSubjectAuthorDiscuss
10/3/2020
10:01
Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that the European Commission (EC) has granted orphan drug designation for FLT190 for the treatment of Fabry Disease, based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
brexitplus
04/3/2020
10:03
Bloody virus temporarily interrupting our uptrend. I recommend AUTO12NG takes on a new viral target !
luxaeterna1
23/2/2020
13:21
Mentioned in the Mail today. hTtps://www.thisismoney.co.uk/money/news/article-8032885/amp/Should-backing-wave-new-firms-pioneering-medical-revolution.html?__twitter_impression=true
acuere
20/2/2020
15:23
Back to £2.50 and back to green. I expect this will steady at £2.55/£2.60 until we have some news from Freeline/Gyroscope. 30% premium to NAV has been normal for this stock in the past, hopefully we have now blown the Woodford cobwebs away and this can resume.
milehouse
18/2/2020
13:55
On a technical basis and analysing Syncona's latest chart it looks like a break out is about to occur.
sev22
17/2/2020
08:08
SYNCONA INVESTOR RELATIONS JUST RELEASED THIS UPDATE - Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders - Oxford, 17 February 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, today announced completion of an extended Series A financing of £27.5 million from existing investors Syncona Ltd (“Syncona̶1;) and Oxford Sciences Innovation (“OSI”) who contributed £16.6 million and £10.4 million respectively. They were joined in the round with £0.5 million from the University of Oxford. This comes after an initial Series A investment of £14 million in 2018 bringing the total series A to £41.5 million.OMass is leveraging its world-class biophysical discovery platform to deliver high-resolution data on how a putative ligand engages with a membrane protein target, focusing on GPCRs and solute carriers. Proceeds from this financing will allow the Company to progress a pipeline of small molecule therapeutics for patients suffering from immunological and genetic disorders providing funding for two years and enabling OMass to progress its lead program into preclinical development. “It is an exciting time in our progression as we discover, develop and ultimately commercialize novel medicines to bring life-changing benefits to patients with immunological and genetic diseases”, said Ros Deegan, Chief Executive Officer, OMass Therapeutics. “I would like to thank our investors, Syncona, OSI and the University of Oxford for their belief in the technology’s ability to deliver new biological insights and new chemical starting points for membrane targets.” “We are pleased to continue to support OMass, a world-leader in native mass spectrometry that allows non-covalent interactions with membrane protein targets to be studied in high-definition,R21; said Dr Edward Hodgkin, Chairman, OMass Therapeutics and Partner at Syncona. “The Company has now initiated programs against three high impact GPCR targets with a focus on genetically defined patient populations as well as immunological dysfunction, and we look forward to OMass progressing its products towards clinical development.” “Emerging biophysical technologies like native mass spectrometry can meaningfully improve drug discovery and impact global health outcomes,” said Lachlan Mackinnon, Principal, Oxford Sciences Innovation. “We formed OSI to turn Oxford’s world beating science into world changing companies and believe that this funding puts us in a position to take full advantage of OMass Therapeutics’ capability to identify novel drugs against membrane proteins.”
sev22
15/2/2020
11:13
The Autolus share price was up 6.6% in the US last night.
sev22
15/2/2020
09:26
It’s truly amazing that such a great company is overlooked by the PI community.....
ltinvestor
14/2/2020
09:23
Published 14 Feb 2020: Gyroscope Therapeutics, a company developing gene therapies and surgical delivery systems for retinal diseases, announces the strengthening of its leadership team with the hiring of Dr. Nadia Waheed from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO) and the promotion of Dr. Jane Hughes, formerly VP Translational Research, to Chief Scientific Officer (CSO). These additions to the Gyroscope Executive Committee come as the company is currently enrolling its initial Phase I/II clinical trial for the lead investigational gene therapy GT005 and preparing to move into its proof of concept Phase II clinical program. Khurem Farooq, Chief Executive Officer, Gyroscope Therapeutics said: “We are delighted to welcome Nadia as CMO and Jane to her new role as CSO. Nadia’s expertise in ophthalmology and understanding of the patient experience will be invaluable at this stage in our development, as we continue to move our clinical programme forward and broaden our reach across the United States and the rest of the world. Jane’s expertise has been critical in building the biological understanding to support our advancement into the clinic. She has a proven track record as a translational biologist who has effectively bridged between pre-clinical and clinical programs. I welcome both to the Gyroscope Executive Committee and look forward to working together to develop our gene therapy for one of the leading causes of vision loss, dry age-related macular degeneration.” Dr Nadia Waheed said: “This is an exciting time for me to join Gyroscope. As a retinal surgeon, and a frequent collaborator with innovative companies, my passion has been to find meaningful solutions for patients facing retinal diseases. GT005 represents a unique approach as a one-time gene therapy that may slow the progression of a blinding disease for patients for whom currently there is no good option. I’m excited to be part of a team that I believe will make a difference for people with dry AMD.” Dr Jane Hughes said: “Over the past year I’ve been privileged to work with the researchers and scientific founders at Gyroscope to better understand the complement system and its role in dry AMD to bring GT005 from an idea in a laboratory to an investigational gene therapy. I’m excited about the next phase of research growth that lies ahead in building the Gyroscope pipeline of medicines.”
sev22
14/2/2020
09:16
New autolus and freeline presentations up on their websites. Check out slides 12-13 of the Freeline one at htTps://www.freeline.life/investors-media/newsroom/?type=presentations for big smiles! Factor IX activity well into 100-150% territory
luxaeterna1
12/2/2020
17:18
(Alliance News) - Syncona Ltd on Wednesday said its investee Freeline Therapeutics has revealed "promising" data from its gene therapy studies for the treatment of Fabry and Gaucher diseases. Syncona holds a 79% stake in Freeline. Fabry disease is a rare genetic disease that affects many parts of the body including the skin, eyes, gastrointestinal system, kidney, heart, brain, and nervous system. Gaucher is an inherited genetic disorder that results in the build-up of certain fatty substances in organs such as the spleen and liver, causing the affected organs to enlarge, thereby affecting their function. Syncona said that preliminary data from the FLT190 study programme for Fabry showed that Freeline's adeno-associated viral gene therapy can deliver sustained levels of the alpha-galactosidase A enzyme from a single treatment. It added that a dose-escalating Phase 1/2 study in adult males with the disease provided encouragement that higher levels of the enzymes could be achieved through dose-escalation. The alpha-galactosidase enzyme can help digest sugars and fats. When it's missing, complex sugars and fats can easily build up within the gut and throughout the body. The enzyme helps the body break carbohydrates, depriving gas production fuel and toxic bacteria. Data from the dose escalation study showed a three to four-fold increase in enzyme activity was achieved by week four, and sustained through the data cut-off at week 20. The biotechnology investment company also said that pre-clinical data in Gaucher disease suggests that the adeno-associated viral gene therapy has therapeutic potential. Data suggests a single injection of its treatment would result in sustained steady levels of fully active beta-glucocerebrosidase enzymes in the bloodstream. Beta-glucocerebrosidase is an enzyme that helps break down a large molecule called glucocerebroside into glucose and simpler fat molecules. "As of the data cut-off date, there have been no infusion-related adverse events. Two adverse events were reported in the study. The patient had elevations in ALT levels and levels returned to normal range within 3 weeks following immune suppression. A grade 2 myocarditis was observed but repeat MRI scans showed no evidence of changes compared to base line and it resolved without specific intervention," said Derralynn Hughes, clinical director of haematology & oncology at the Royal Free Hospital London. Syncona shares were trading 0.6% higher in London on Wednesday afternoon at 237.00 pence each.
sev22
12/2/2020
14:10
ANNOUNCED AT 2.00 PM: Freeline presents clinical data at 16th Annual WORLDSymposiumTM 12 February 2020 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes that its portfolio company Freeline today announced data at the 16th annual WORLDSymposiumTM in Orlando, Florida, 10th - 13th February 2020. Preliminary data were presented on the starting dose in a Phase 1/2 dose escalation study for Fabry Disease, the first AAV gene therapy study in Fabry Disease globally, and pre-clinical data was presented in Gaucher Disease. · Promising preliminary data presented in Fabry Disease; demonstrating for the first time that AAV gene therapy can deliver sustained levels of the enzyme αGLA[1] from a single infusion · Freeline has demonstrated that it is able to deliver high protein levels in its Phase 1/2 trial in Haemophilia B at higher doses, which provides encouragement that higher αGLA levels could be achievable in Fabry through dose escalation · Encouraging preclinical data in Gaucher Disease suggesting that AAV liver-directed gene therapy has therapeutic potential The announcement can be accessed on Freeline's website at: http://www.freelinetx.com
sev22
12/2/2020
08:48
I am not sure whether someone has already posted a feature from John Rosier in the Investors Chronicle about three weeks ago. He holds 3% of Syncona in his 2020 portfolio and said that the Autolus overhang, which depressed the share price last year, had now cleared and he was expecting an imminent re-rating in the stock. Apparently Syncona's shares historically manage a 30% plus premium to net asset value (NAV)which equates to a minimum of £2.60. The other reason he continues to hold is the company's excellent record of creating real value in the life sciences industry.
sev22
09/2/2020
09:44
Freeline alone in which Syncona own 80% could be worth the present mkt cap in 24 months time!
ltinvestor
08/2/2020
10:03
htTps://www.synconaltd.com/transformational-treatments/ Video update on the Freeline RNS.
luxaeterna1
07/2/2020
21:08
Yeah, this level of response is nearing the "will survive serious surgery" levels of FIX activity.
luxaeterna1
07/2/2020
16:10
Wonderful results for those suffering from the illness
ltinvestor
07/2/2020
14:04
Interesting freeline RNS out, if I'm not mistaken, this is the first trial ever to "cure" the haemophilia FIX to normal levels. Time will tell and there are several hurdles to go.
luxaeterna1
05/2/2020
20:57
Tiger Blue, that's a good and fair write up. It was the emphasis on the platforms which I thought very enlightening, and encouraging. But much else also well worth listening to.
rambutan2
05/2/2020
12:12
Syncona is a 'strong buy' having just hit its 200 day moving average of 231.00.
sev22
05/2/2020
12:03
TB.I believe that Autolus will be taken out for many times it’s present mkt cap but time will tell....
ltinvestor
05/2/2020
11:42
DL - lol, but in this case I think heavier is better
tiger blue
05/2/2020
11:32
Is he on a diet then? Seems keen to get on the scales....... DL
davidlloyd
05/2/2020
10:49
CM day was indeed successful. Webcast recording on SYNC website, as always DYOR but do please watch if you have more than a passing interest. These are not annual or even bi-annual events for SYNC, and there is a lot of insight and an opportunity to learn about the whole current portfolio, which certainly gave me reassurance about my holding. Positives: there will be lots of newsflow to come from Freeline, Achilles and Gyroscope over the next 12-24 months as these are scaling rapidly. I think the reason share price has responded is the focus on the platforms and manufacturing they are building, that enable new products to be rolled out quicker and more efficiently. The takeover of Spark Therapeutics by Roche for $4.3bn was referenced, the price paid was far too much for the Haemophilia candidates they have, they bought it mainly for the platform. All of Syncona’s companies have a strong focus on the manufacturing of product in reliable, closed processes. Note that the recent Autolus data showed vastly superior survival rates from the closed manufacturing process vs the open. The presentation and panel discussions showed the value of being close to the science (literally 200 yds from UCL) and the benefit of sharing ideas and experience among the companies, as well as their long term approach which the scientists & founders prefer to venture cap, who always put the exit strategy on the first page. Concerns/negatives: Not many, though Brexit could be a pain in adding extra costs for different regulations in UK/EU, and long term may require manufacturing to be set up in EU as well as UK/US. Attracting European recruits may also be harder. Autolus (my view & I still hold) - I think you have to say given the share price that the jury is out as to whether they will ever get a product to market, the data is encouraging but there are other players. Price already heavily down so only 11% of SYNC portfolio and I think Freeline will be much bigger soon, but scope for a big bounce should AUTL succeed. Share price – I wouldn’t have been brave enough but someone asked Martin Murphy about the share price and I’ll end with a direct quote from him – “We can’t manage the share price, what we can do is manage the business….in the long run we all get weighed, and I’m looking forward to being weighed, because frankly the value will come out”.
tiger blue
Chat Pages: 756  755  754  753  752  751  750  749  748  747  746  745  Older
ADVFN Advertorial
Your Recent History
LSE
SYNC
Syncona
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220817 08:24:35